Article

Identification of Candidate Growth Promoting Genes in Ovarian Cancer through Integrated Copy Number and Expression Analysis

VBCRC Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
PLoS ONE (Impact Factor: 3.23). 04/2010; 5(4):e9983. DOI: 10.1371/journal.pone.0009983
Source: PubMed

ABSTRACT

Ovarian cancer is a disease characterised by complex genomic rearrangements but the majority of the genes that are the target of these alterations remain unidentified. Cataloguing these target genes will provide useful insights into the disease etiology and may provide an opportunity to develop novel diagnostic and therapeutic interventions. High resolution genome wide copy number and matching expression data from 68 primary epithelial ovarian carcinomas of various histotypes was integrated to identify genes in regions of most frequent amplification with the strongest correlation with expression and copy number. Regions on chromosomes 3, 7, 8, and 20 were most frequently increased in copy number (> 40% of samples). Within these regions, 703/1370 (51%) unique gene expression probesets were differentially expressed when samples with gain were compared to samples without gain. 30% of these differentially expressed probesets also showed a strong positive correlation (r > or =0.6) between expression and copy number. We also identified 21 regions of high amplitude copy number gain, in which 32 known protein coding genes showed a strong positive correlation between expression and copy number. Overall, our data validates previously known ovarian cancer genes, such as ERBB2, and also identified novel potential drivers such as MYNN, PUF60 and TPX2.

Download full-text

Full-text

Available from: Kylie Gorringe, Aug 21, 2014
  • Source
    • "FAM83D excutes these biological functions at least in part through regulation of the tumor suppressor gene FBXW7 [4]. The fact that FAM83D expression is elevated in hepatocellular carcinoma [5, 6], ovarian cancer [7] and metastatic lung adenocarcinomas [8] suggests the possibility that FAM83D is an oncogene for additional cancer types. In this study, using recently available cancer genomic data from 'The Cancer Genome Atlas' (TCGA), we investigated the prognostic significance of FAM83D expression across 22 human cancer types. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The family with sequence similarity 83, member D (FAM83D) gene has been proposed as a new prognostic marker for breast cancer. Here we further evaluate the prognostic significance of FAM83D expression in different breast cancer subtypes using a meta-analysis. Patients with higher FAM83D mRNA levels have significantly decreased overall and metastatic relapse-free survival, particularly in the group of patients with ER-positive, or luminal subtype tumors. We also assessed FAM83D alterations and its prognostic significance across 22 human cancer types using The Cancer Genome Atlas (TCGA). FAM83D is frequently gained in the majority of human cancer types, resulting in the elevated expression of FAM83D. Higher levels of FAM83D mRNA expression are significantly associated with decreased overall survival in several cancer types. Finally, we demonstrate that TP53 mutation in human cancers is coupled to a significant increase in the expression of FAM83D, and that a higher level of FAM83D expression is positively correlated with an increase in genome instability in many cancer types. These results identify FAM83D as a potential novel oncogene across multiple human cancer types.
    Full-text · Article · Dec 2015 · Oncotarget
  • Source
    • "Functional aberration of the mitotic spindle may lead to errors in chromosome segregation and aneuploidy, which are often seen in advanced human cancers. Various microarray studies suggest that FAM83D expression is elevated in hepatoacellular carcinoma [19], ovarian cancer [20] and metastatic lung adenocarcinomas [21]. However, the function and mechanism of FAM83D in tumorigenesis has not yet been studied. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Amplification of chromosome 20q is frequently found in various types of human cancers, including breast cancer. The list of candidate oncogenes in 20q has expanded over the past decade. Here, we investigate whether FAM83D (family with sequence similarity 83, member D) on chromosome 20q plays any role in breast cancer development. The expression level of FAM83D is significantly elevated in breast cancer cell lines and primary human breast cancers. High expression levels of FAM83D are significantly associated with poor clinical outcome and distant metastasis in breast cancer patients. We show that ectopic expression of FAM83D in human mammary epithelial cells promotes cell proliferation, migration and invasion along with epithelial-mesenchymal transition (EMT). Ablation of FAM83D in breast cancer cells induces apoptosis and consequently inhibits cell proliferation and colony formation. Mechanistic studies reveal that overexpression of FAM83D downregulates FBXW7 expression levels through a physical interaction, which results in elevated protein levels of oncogenic substrates downstream to FBXW7, such as mTOR, whose inhibition by rapamycin can suppress FAM83D-induced cell migration and invasion. The results demonstrate that FAM83D has prognostic value for breast cancer patients and is a novel oncogene in breast cancer development that at least in part acts through mTOR hyper-activation by inhibiting FBXW7.
    Full-text · Article · Nov 2013 · Oncotarget
  • Source
    • "Just recently, we generated Zfatf/f-Cd4Cre mice [6], and showed that Zfat-deficient mice exhibited a reduction in the number of peripheral T cells with decreased surface expression of IL-7Rα and T cell antigen receptor (TCR)-stimulation-induced expression of CD25 and IL-2, indicating that Zfat is required for peripheral T cell homeostasis [6]. On the other hand, genetic variants of ZFAT have also been reported to be associated with adult height in Japanese and Korean population [7], [8] and several common diseases including hypertension and cancer [9], [10]. Of great interest is that a genetic variant of ZFAT is reported to be strongly associated with interferon-β responsiveness in multiple sclerosis [11] and the severity of Hashimoto’s disease [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The human ZFAT gene was originally identified as a susceptibility gene for autoimmune thyroid disease. Mouse Zfat is a critical transcriptional regulator for primitive hematopoiesis and required for peripheral T cell homeostasis. However, its physiological roles in T cell development remain poorly understood. Here, we generated Zfat (f/f)-LckCre mice and demonstrated that T cell-specific Zfat-deletion in Zfat (f/f)-LckCre mice resulted in a reduction in the number of CD4(+)CD8(+)double-positive (DP) cells, CD4(+)single positive cells and CD8(+)single positive cells. Indeed, in Zfat (f/f)-LckCre DP cells, positive selection was severely impaired. Defects of positive selection in Zfat-deficient thymocytes were not restored in the presence of the exogenous TCR by using TCR-transgenic mice. Furthermore, Zfat-deficient DP cells showed a loss of CD3ζ phosphorylation in response to T cell antigen receptor (TCR)-stimulation concomitant with dysregulation of extracellular signal-related kinase (ERK) and early growth response protein (Egr) activities. These results demonstrate that Zfat is required for proper regulation of the TCR-proximal signalings, and is a crucial molecule for positive selection through ERK and Egr activities, thus suggesting that a full understanding of the precise molecular mechanisms of Zfat will provide deeper insight into T cell development and immune regulation.
    Full-text · Article · Oct 2013 · PLoS ONE
Show more